Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2016

Abuse and diversion of immediate release opioid analgesics as
compared to extended release formulations in the United States
Janetta L. Iwanicki
Denver Health and Hospital Authority, Denver

S. Geoff Severtson
Denver Health and Hospital Authority, Denver

Heather McDaniel
Denver Health and Hospital Authority, Denver

Andrew Rosenblum
National Development and Research Institutes, Incorporated, New York

Chunki Fong
National Development and Research Institutes, Incorporated, New York

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Iwanicki, Janetta L.; Severtson, S. Geoff; McDaniel, Heather; Rosenblum, Andrew; Fong, Chunki; Cicero,
Theodore J.; Ellis, Matthew S.; Kurtz, Steven P.; Buttram, Mance E.; and Dart, Richard C., ,"Abuse and
diversion of immediate release opioid analgesics as compared to extended release formulations in the
United States." PLoS One. 11,12. e0167499. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5547

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Janetta L. Iwanicki, S. Geoff Severtson, Heather McDaniel, Andrew Rosenblum, Chunki Fong, Theodore J.
Cicero, Matthew S. Ellis, Steven P. Kurtz, Mance E. Buttram, and Richard C. Dart

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/5547

RESEARCH ARTICLE

Abuse and Diversion of Immediate Release
Opioid Analgesics as Compared to Extended
Release Formulations in the United States
Janetta L. Iwanicki1*, S. Geoff Severtson1, Heather McDaniel1, Andrew Rosenblum2,
Chunki Fong2, Theodore J. Cicero3, Matthew S. Ellis3, Steven P. Kurtz4, Mance
E. Buttram4, Richard C. Dart1

a11111

1 Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, Colorado, United
States of America, 2 National Development and Research Institutes, Incorporated, New York, New York,
United States of America, 3 Department of Psychiatry, Washington University School of Medicine, St. Louis,
Missouri, United States of America, 4 Center for Applied Research on Substance Use and Health Disparities,
Nova Southeastern University, Fort Lauderdale, Florida, United States of America
* Janetta.iwanicki@rmpdc.org

Abstract
OPEN ACCESS
Citation: Iwanicki JL, Severtson SG, McDaniel H,
Rosenblum A, Fong C, Cicero TJ, et al. (2016)
Abuse and Diversion of Immediate Release Opioid
Analgesics as Compared to Extended Release
Formulations in the United States. PLoS ONE 11
(12): e0167499. doi:10.1371/journal.
pone.0167499
Editor: Ruth Landau, University of Washington,
UNITED STATES
Received: May 7, 2016

Background
Therapeutic use and abuse of prescription opioids in the United States increased substantially between 1990 and 2010. The Centers for Disease Control estimated deaths related to
pharmaceutical opioids reached nearly 19,000 in 2014. Of prescription opioids sold, 10%
are extended release (ER) and 90% immediate release (IR). However, most regulations and
interventions have focused on decreasing ER abuse. Our objective was to compare rates of
abuse and diversion of ER and IR opioid analgesics over time using multiple surveillance
programs.
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Methods
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Rates of abuse and diversion of ER and IR opioid formulations were compared using data
from four surveillance programs in the Researched Abuse, Diversion and Addiction Related
Surveillance (RADARS®) System. Data were evaluated from 2009 through 2015, and Poisson regression used to compare IR and ER opioid cases over time.

Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.

Results

Funding: The RADARS System is supported by
subscriptions from pharmaceutical manufacturers
for surveillance, research and reporting services.
RADARS System is the property of Denver Health
and Hospital Authority, a political subdivision of the
State of Colorado. Denver Health retains exclusive
ownership of all data, databases and systems.
Subscribers do not participate in in data collection

From 2009 to 2015, IR opioids were prescribed at a rate 12 to 16 times higher than ER. In
the Poison Center Program, population-adjusted rates of Intentional Abuse for IR were 4.6
fold higher than ER opioids (p<0.001). In the Drug Diversion Program, population-adjusted
rates of diversion were 6.1 fold higher for IR than ER opioids (p<0.001). In the Opioid Treatment Program, population-adjusted rates of endorsements for abuse were 1.6 fold higher
for IR opioids than ER (p = 0.002). In the Survey of Key Informants’ Patients Program, population-adjusted rates of endorsements for abuse were 1.5 fold higher for IR opioids than ER
(p<0.001).
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or analysis, nor do they have access to the raw
data. This study was not sponsored or funded by
any subscriber. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no additional competing interests exist.

Conclusions
Between 2009 and 2015, IR opioids were prescribed at a much higher rate than ER opioids.
Results from four surveillance programs show population-adjusted rates of prescription opioid abuse were markedly higher for IR than ER medications. For the greatest public health
benefit, future interventions to decrease prescription opioid abuse should focus on both IR
and ER formulations.

Introduction
Therapeutic use of prescription opioids increased substantially between 1990 and 2010. In
concert, abuse and diversion of opioids increased dramatically, resulting in increased contacts
with poison centers, visits to emergency departments, admissions to substance abuse treatment
centers, and deaths. [1–3] The Centers for Disease Control (CDC) estimated deaths related to
pharmaceutical opioids reached nearly 19,000 in 2014. [4] The epidemic of prescription opioid
abuse remains an alarming public health concern with severe sequelae and massive public
health costs. [5–9]
Several interventions to decrease prescription opioid abuse have focused predominantly on
extended release (ER) formulations. The United States Food and Drug Administration (US
FDA) expressed strong concerns for the potential of increased serious side effects associated
with ER medications, often available in higher milligram concentrations per unit dose. A Risk
Evaluation and Mitigation Strategy (REMS) program was developed by the FDA for ER and
long-acting (ER/LA) opioids, focusing on risk management via provider education on safe
prescribing practices, patient counseling, and patient education. Additionally, the FDA and
pharmaceutical companies have focused on developing abuse deterrent formulations (ADFs)
to decrease ER opioid abuse. However, the US market share for ER opioids is only 10%, while
immediate release (IR) products account for 90% of opioid analgesic prescriptions dispensed.
[10,11] Previous research suggests a majority of people who abuse prescription opioids initiated their abuse with IR medications, commonly prescribed for acute pain by primary care
physicians. [12–14] Despite their ubiquity, most IR formulations are not subject to REMS or
other similar regulations.
Given the wide availability of IR opioids, and their common use to treat acute pain in primary care settings, we hypothesized they contribute greatly to the prescription opioid abuse
epidemic. We aimed to compare rates of abuse and diversion of ER to IR opioid analgesic formulations in the US using multiple surveillance programs.

Materials and Methods
Rates of abuse and diversion of ER and IR opioid formulations were compared using data
from the Researched Abuse, Diversion and Addiction Related Surveillance (RADARS1) System, a real-time surveillance system that measures prescription drug abuse and diversion for
specific products across the US. RADARS System is comprised of a mosaic of programs, each
with an independent principal investigator (PI) and unique methodology, which gather data
from different populations and provide multiple views on prescription drug abuse. RADARS
System is independently owned and operated by Denver Health and Hospital Authority,
which operates the public hospital for the city and county of Denver. RADARS System is supported by subscriptions from pharmaceutical companies that use the data in reporting to the
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FDA. Subscribers had no role in conception, execution, or reporting of this analysis. Each program is approved by the institutional review board of the PI’s institution. Data from four
RADARS programs (Poison Center (PC), Drug Diversion (DD), Opioid Treatment (OTP),
Survey of Key Informants’ Patients (SKIP)) were used. Further details regarding each program
have been published. [15]
For this analysis from 2009 through 2015, products were grouped based on formulation as
either IR or ER. Active pharmaceutical ingredients (APIs) of interest were oxycodone, hydrocodone, morphine, hydromorphone, oxymorphone, tramadol, and tapentadol.
The Poison Center (PC) Program studies acute health events from calls from the general
population, caregivers, and healthcare providers regarding potentially toxic exposures. Trained
specialists at each center collect data using a nationally standardized electronic health record.
Data are summarized quarterly. Intentional Abuse exposures were defined by the National
Poison Data System definition of an exposure resulting from intentional improper or incorrect
use of a substance where the patient was attempting to gain a high, euphoria, or another psychotropic effect. PC cases were defined as the sum of exposure calls mentioning at least one
drug within the category. Exposure calls where both an IR and ER opioid were mentioned
were counted as a case in each group.
The Drug Diversion (DD) Program provides systematic surveillance data on diversion of
drugs. Drug diversion officers submit data quarterly on the number of diversion cases within
their jurisdiction. Drug diversion officers represent municipal police departments, multi-jurisdictional drug task forces, county sheriffs’ departments, regulatory agencies, state police
agencies, prosecutors’ offices, and departments of health. DD reports are defined as the total
number of documented drug diversion cases involving products of interest with investigation
that results in a written complaint or report.
The Opioid Treatment Program (OTP) monitors the prevalence of prescription opioid
abuse among admissions to federally approved opioid agonist treatment programs. The Survey
of Key Informants’ Patients (SKIP) Program collects data from patients entering substance
abuse treatment programs (excluding methadone programs). At enrollment, each patient is
offered the opportunity to complete a standardized self-administered questionnaire on specific
prescription drugs abused “to get high” in the past 30 days. Cases are defined in OTP and
SKIP programs as the number of survey respondents who endorse at least one opioid product
in the category. After second quarter 2011, tramadol was no longer broken out into IR and ER
on the questionnaire.

Statistical Methods
Rates were calculated by taking the number of cases from a program within a covered 3-digit
zip code and dividing by the associated denominator. Three separate denominators were used,
population, prescriptions dispensed, and grams dispensed. Population rates used estimates by
3-digit ZIP code obtained from the 2000 and 2010 United States Census. Data are extrapolated
for each year quarter subsequent to 2010. Quarterly population rates were calculated by dividing the total number of cases by the sum of the population within 3-digit ZIP code. Prescriptions and grams dispensed estimates were obtained from IMS Health (IMS Government
Solutions, Inc. a subsidiary of IMS Health, Inc.) for IR and ER opioids for each quarter and for
each 3 digit ZIP code within the US. Prescription and grams dispensed rates were calculated
by dividing the total number of cases by the sum of the prescriptions or grams dispensed
within 3-digit ZIP codes. Grams dispensed were used for analysis instead of morphine equivalent dose (MED) because the precise value of MED vary by source and across active pharmaceutical ingredients (API). These differences can produce large changes in the data and over or
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under-estimate abuse rates. Additionally, MED is used to determine analgesic effect by titration, which may or may not correlate with the amount of a given opioid sought to achieve
when abusing an opioid. [16]
Poisson regression, log-linear regression for modeling case count data [17], was used with
an over/under dispersion parameter to compare IR and ER opioid counts over time. Rates
were modeled by including the natural log of the denominator (population, prescriptions or
grams dispensed) as an offset term. Polynomial terms for quarter were also included in the
models and the highest significant term for either drug group and all lower order terms were
kept to assess trends. These models were used to calculate the expected rate for the IR and ER
groups in fourth quarter 2015

Results
IR opioids were dispensed in much greater quantities than ER opioids, with 12 to 16 times
greater prescriptions supplied and 3 to 7 times greater grams dispensed for IR as for ER opioids in each quarter from 2009 to 2015 (Fig 1).

Poison Center Program Intentional Abuse
The population-adjusted rate of Intentional Abuse for IR was significantly higher than ER opioids. In fourth quarter 2015, IR rate was 0.160 exposures per 100,000 population (95%CI
0.145–0.176), while ER was 0.035 (95%CI 0.029–0.042), a 4.6 fold difference (p<0.001, Fig 2A).
The prescription-adjusted rate of ER abuse was significantly higher than IR. In fourth quarter 2015, the IR rate was 0.101 exposures per 10,000 prescriptions (95%CI 0.093–0.110), while
ER was 0.283 (95%CI 0.229–0.350), a 2.8 fold difference (p<0.001, Fig 2B).
The grams-adjusted rate of ER abuse was significantly higher than IR. In fourth quarter
2015, the IR rate was 0.790 exposures per 100,000 grams (95%CI 0.715–0.873), while ER was
1.071 (95%CI 0.861–1.332) a 1.4 fold difference (p = 0.013, Fig 2C).

Drug Diversion
The population-adjusted rate of diversion was significantly higher for IR than ER opioids. In
fourth quarter 2015, IR rate was 0.709 diversion reports per 100,000 population (95%CI 0.601–
0.836), while ER was 0.116 (95%CI: 0.084, 0.161), a 6.1 fold difference (p<0.001, Fig 3A).
The prescription-adjusted rate of ER opioid diversion was significantly higher than IR. In
fourth quarter 2015, the IR rate was 0.446 diversion reports per 10,000 prescriptions (95%CI
0.378–0.525), while ER was 0.916 (95%CI 0.676–1.242), a 2.1 fold difference (p<0.001, Fig 3B).
The grams-adjusted rate of IR opioid diversion was similar to the ER rate, with IR slightly
higher than ER. In fourth quarter 2015, the IR rate was 3.501 diversion reports per 100,000
grams (95%CI 2.973–4.123), while ER was 3.386 (95%CI 2.474–4.635), a 1.0 fold difference
(p = 0.853, Fig 3C).

Opioid Treatment Program
The population-adjusted rate of endorsements for abuse was significantly higher for IR opioids
than ER. In fourth quarter 2015, the IR rate was 0.446 endorsements per 100,000 population
(95%CI 0.369–0.539), while ER was 0.278 (95%CI 0.221–0.349), a 1.6 fold difference (p =
0.002, Fig 4A).
The prescription-adjusted rate of ER opioid endorsements was significantly higher than IR.
In fourth quarter 2015, the IR rate was 0.286 endorsements per 10,000 prescriptions (95%CI
0.234–0.349), while ER was 2.207 (95%CI 1.680–2.901), 7.7 fold difference (p<0.001, Fig 4B).
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Fig 1. Prescriptions and grams dispensed for immediate release (IR) and extended release (ER)
opioid analgesics by quarter and formulation. Data are displayed according to calendar quarter. (A)
Number of prescriptions dispensed for IR and ER opioid analgesic formulations. (B) Number of grams of drug
dispensed for IR and ER opioid formulations. (IMS Health).
doi:10.1371/journal.pone.0167499.g001
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Fig 2. Rates of IR and ER opioid analgesic Intentional Abuse, RADARS System Poison Center Program. Data are displayed
according to calendar quarter. (A) Rates of Intentional Abuse adjusted for population; a cubic model was fit for both IR and ER formulations
over time. (B) Rates adjusted for prescriptions dispensed; a quadratic model was fit for both IR and ER formulations over time. (C) Rates
adjusted for grams dispensed; a quadratic model was fit for both IR and ER formulations over time. The red boxes represent the point with
the highest expected rate during the study period.
doi:10.1371/journal.pone.0167499.g002

The grams-adjusted rate of ER opioid endorsements was significantly higher than IR. In
fourth quarter 2015, the IR rate was 2.295 endorsements per 100,000 grams (95%CI 1.843–
2.857), while ER was 8.430 (95%CI 6.415–11.077), 3.7 fold difference (p<0.001, Fig 4C).

Survey of Key Informants’ Patients
The population-adjusted rate of endorsements for abuse was significantly higher for IR opioids
than ER. In fourth quarter 2015, the IR rate was 0.396 endorsements per 100,000 population
(95%CI 0.352–0.445), while ER was 0.273 (95%CI 0.235–0.317), a 1.5 fold difference (p<0.001,
Fig 5A).

PLOS ONE | DOI:10.1371/journal.pone.0167499 December 9, 2016

6 / 12

Immediate Release and Extended Release Opioid Abuse and Diversion

Fig 3. Rates of IR and ER opioid analgesic diversion, RADARS Drug Diversion Program. Data are displayed according
to calendar quarter. (A) Rates of endorsement adjusted for population. (B) Rates adjusted for prescriptions dispensed. (C)
Rates adjusted for grams dispensed. For each, a cubic model was fit for both IR and ER formulations over time. The red boxes
represent the point with the highest expected rate during the study period.
doi:10.1371/journal.pone.0167499.g003

Fig 4. Rates of IR and ER opioid analgesic endorsement, RADARS Opioid Treatment Program. Data are displayed according
to calendar quarter. (A) Rates of endorsement adjusted for population. (B) Rates adjusted for prescriptions dispensed. (C) Rates
adjusted for grams dispensed. For each, a cubic model was fit for both IR and ER formulations over time. The red boxes represent
the point with the highest expected rate during the study period.
doi:10.1371/journal.pone.0167499.g004
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Fig 5. Rates of IR and ER opioid analgesic endorsement, RADARS Survey of Key Informants’ Patients Program.
Data are displayed according to calendar quarter. (A) Rates of endorsement adjusted for population. (B) Rates adjusted for
prescriptions dispensed. (C) Rates adjusted for grams dispensed. For each, a cubic model was fit for both IR and ER
formulations over time. The red boxes represent the point with the highest expected rate during the study period.
doi:10.1371/journal.pone.0167499.g005

The prescription-adjusted rate of ER opioid endorsements was significantly higher than IR.
In fourth quarter 2015, the IR rate was 0.247 endorsements per 10,000 prescriptions (95%CI
0.224–0.274), while ER was 2.208 (95%CI 1.889–2.581), a 8.9 fold difference (p<0.001, Fig 5B).
The grams-adjusted rate of ER opioid endorsements was significantly higher than IR. In
fourth quarter 2015, the IR rate was 1.941 endorsements per 100,000 grams (95%CI 1.722–
2.186), while ER was 8.401 (95%CI 7.126–9.904), a 4.3 fold difference (p <0.001, Fig 5C).

Discussion
Four different perspectives on prescription opioid abuse and diversion indicate that IR opioids
affect a much larger absolute number of individuals than ER opioids. IR opioids are prescribed
at a rate 12 to 16 times higher than ER, and dispensed in 3 to 7 times greater milligram quantities, greatly increasing their availability and the number of patients exposed. Despite evaluating
unique populations, each program revealed the same trend: abuse and diversion of IR products
exceeded ER after adjustment for population. The relative difference between the rate of IR
and ER diversion and abuse was greatest in the Drug Diversion and Poison Center Programs,
while the smallest difference was seen in treatment programs (OTP and SKIP). The smaller
effect in treatment programs suggests that while high-risk experienced people who abuse prescription opioids still abuse IR medications more frequently, they also seek out ER medications
at a higher rate than people who abuse opioids more casually.
The high rates of IR abuse have significant public health implications in addressing the prescription opioid epidemic. Our results are consistent with previous work showing the direct
relation between increased drug availability and increased abuse. [18,19] Additionally, treatment for acute pain almost always involves an IR opioid analgesic, which may transition to an
ER product if chronic treatment is needed. A significant proportion of the population of

PLOS ONE | DOI:10.1371/journal.pone.0167499 December 9, 2016

8 / 12

Immediate Release and Extended Release Opioid Abuse and Diversion

patients with pain has predisposing factors for addiction, ranging from genetic to psychosocial,
regardless of whether they are “appropriately treated” in the clinic. [20] Once patients with
risk factors are exposed, some will progress to abuse and addiction, and as the exposed population increases, so does the number of at-risk patients exposed.
While well-intentioned, some federal and state policy makers, as well as payors, have missed
a prime opportunity for intervention in the prescription opioid epidemic by focusing primarily
on the regulation and control of ER opioids and failing to adequately address IR opioid abuse.
[4] This strategy would be expected to address a relatively smaller number of high-risk people
who abuse opioids who preferentially seek ER products. However, interventions focusing on
IR formulations have the potential to impact a much larger number of individuals, many of
whom are initiating opioid abuse. [21] Impeding IR abuse has the potential to halt the natural
progression of medication abuse and addiction at a much earlier stage. [22] Therefore, future
interventions should target both IR and ER medications. A broader approach will require
more resources, but without addressing both formulations, high risk people who abuse opioids
who are already addicted are likely to simply switch from ER to IR formulations, and the much
larger population abusing IR medications is missed completely. [12,23]
In contrast to population-adjusted rates, prescription-adjusted rates of abuse and diversion were higher for ER than IR opioids across all four programs. However, when adjusted
for grams dispensed, the effect size was diminished in the PC and treatment programs (OTP
and SKIP), consistent with a high-risk population still preferring to abuse ER medications.
This may be due to high milligram doses available in a single tablet, making it easier to
obtain large milligram quantities to support their addiction even if they are only abusing
orally. [23] Interestingly, when adjusted for grams dispensed, IR opioids were diverted at a
higher rate than ER, though this difference was not statistically significant. This suggests
that after interventions focusing on ER formulations such as the introduction of ADFs, IR
medications may have higher market value on the streets, or potentially IR medications are
being diverted in higher milligram dose forms than in the past. [24] Data from the website
StreetRx.com, where users enter the price paid for drugs purchased on the street, show that
IR oxycodone has a typical street price 30–35% higher per milligram than ER oxycodone as
of 2015. [25]
Rates of abuse and diversion peaked in all four programs by the end of 2010, matching
trends seen in previous research. [5,26] With the exception of the Survey of Key Informants’
Patients Program, rates of abuse and diversion declined between 2010 and 2015 for both IR
and ER formulations in all programs. In most programs, if current trends continue it is possible that prescription-adjusted rates of abuse and diversion for IR opioids will exceed ER in the
very near future. Additionally, the amount (grams dispensed) of IR opioids rose dramatically
between 2009 and 2012, just as grams dispensed of ER gradually declined. This observation
suggests a concerning change in practice toward writing larger prescriptions for IR opioids.
There are several possible explanations for the prominent decrease in prescription-adjusted
rates for ER medications. Many interventions, including REMS and ADFs [27,28], focused
heavily on ER opioids. Patients and healthcare providers may perceive ER medications as
more dangerous, with media coverage often focusing on brand-name ER medications. Widely
publicized events such as policy changes leading to closing pill mills in Florida [6,7], release of
the first ADF ER opioid medication OxyContin [29], and the CDC report of an HIV outbreak
in Indiana associated with intravenous use of ER oxymorphone [30] have predominantly
focused on risks associated with ER medications. This may lead to more cautious prescribing
and patient use of ER medications. Additionally, some people who abuse opioids have
switched from their previous ER drug of choice due to ADF formulations and new restrictions
to an IR formulation that is easier to obtain and abuse.
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There are several limitations to this study. Poison Center Program data are spontaneously
reported, and represent a subset of all possible cases. Additionally, the Opioid Treatment Program and Survey of Key Informants Patients Program rely on self-report and accurate product
identification by participants. Finally, the Drug Diversion Program represents only a small
portion of all nationwide diversion cases. However, despite these limitations, broad geographic
coverage of all of these programs [15], independent data sources and methods for each program, as well as similar trends seen throughout all programs, suggest validity of these findings.
Finally, while ER and IR opioids are treated as mutually exclusive categories in this analysis,
some people who abuse opioids likely use both categories of opioids. While it is true that people who abuse prescription opioids may abuse IR medications, ER medications, or both, the
natural history of prescription opioid abuse suggests that many of these people will move back
and forth between these three groups over time. We chose to analyze IR and ER independently
because the choice of opioid is multi-factorial and often depends on what medications are
available, the costs of those medications, and which medications are available in the most
desired formulations. Additionally, some people who abuse prescription opioids likely abuse
other drugs as well, such as benzodiazepines and heroin, however this polysubstance abuse is
beyond the scope of this study.

Conclusions
Results from four surveillance programs show abuse and diversion of IR opioids affect a much
larger absolute number of individuals than ER opioids. IR opioids are prescribed at a much
higher rate than ER, and population-adjusted rates of abuse and diversion of IR opioids are
higher than for ER in all four programs. However, prescription-adjusted rates for ER medications are higher than those for IR. Trends over time show declining rates of prescription opioid
abuse and diversion for both IR and ER opioids since 2010 in most programs, but prescription-adjusted rates are declining much more rapidly for ER than for IR medications. Future
interventions to decrease abuse of prescription opioids in the US should focus on both IR and
ER formulations.
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